The continuum between amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is well known spectrum of disease and genetic variability in this overlap has been previously reported. We report a novel clinical phenotype of early-onset ALS and FTD with a previously reported <i>SNCB</i> (β synuclein) mutation with Lewi body dementia. 45-year-old woman presented to our department complaining of progressive quadriparesis and dysphagia, which had started with right hemiparesis 4 months ago. She had a history of hypothyroidism but denied neurological family history. Neurologic examination revealed Hoffmann sign positive bilaterally and hyperreflexia of both knees. Nerve conduction study and electromyography showed low complex motor action potentials and widespread denervation in four limbs and thoracic paraspinal muscles without abnormal sensory nerve action potentials. CSF study was unremarkable. Diagnosis of probable ALS was established and riluzole 100mg daily was administered. Three months later, she reported a cognitive decline. In the neuropsychologic assessment battery, her language, memory, and frontal/executive function were below the first percentile for her age with relatively intact attention and visuospatial function. Brain MRI showed bilateral temporal atrophy, especially in the left anterior temporal area. SPECT revealed hypoperfusion in both frontal, temporal, and parietal cortices. Targeted next generation sequencing was conducted for ALS and FTD, and we found heterozygous c.208G>A mutation in <i>SNCB</i>. Despite tremendous research elucidating ALS-FTD, early onset case is rare. With this case, we report a new clinical phenotype of ALS-FTD with <i>SNCB</i> mutation, which has been only reported in few cases of Lewy body dementia and is being investigated recently. This case implies <i>SNCB,</i> which is assumed to contribute to neurodegeneration, can be a new candidate of ALS-FTD, especially in young age.
Read full abstract